Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807309 | 0.81 | PTGDR2 (0.46) | ALDH1A1OPRM1CHRM3AGERMTNR1A | |
| SCHEMBL4807302 | 0.81 | PTGDR2 (0.46) | ALDH1A1OPRM1CHRM3AGERMTNR1A | |
| SCHEMBL3370759 | 0.80 | AGER (0.55) | L3MBTL1LMNAHSD17B10OPRM1CHRM3 | |
| SCHEMBL803780 | 0.80 | PTGDR2 (0.46) | ALDH1A1OPRM1AGER | |
| SCHEMBL27596342 | 0.79 | CCR5 (0.48) | L3MBTL1LMNAOPRM1SLC6A2SLC6A4 | |
| SCHEMBL13434086 | 0.79 | CCR5 (0.59) | L3MBTL1ALDH1A1 | |
| SCHEMBL20780570 | 0.78 | HTR2A (0.65) | — | |
| SCHEMBL9654034 | 0.78 | OPRM1 (0.67) | OPRM1CHRM3 | |
| SCHEMBL3817342 | 0.78 | SLC6A4 (0.50) | OPRM1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL9456418 | 0.78 | AGER (0.58) | L3MBTL1ALDH1A1OPRM1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | L3MBTL1 3941/4885ALDH1A1 683/4885LMNA 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.